Please login to the form below

Not currently logged in
Email:
Password:

rucaparib

This page shows the latest rucaparib news and features for those working in and with pharma, biotech and healthcare.

First-line ovarian approval cements AZ’s Lynparza lead

First-line ovarian approval cements AZ’s Lynparza lead

Lynparza is already well in front of its PARP inhibitor rivals, Tesaro’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).

Latest news

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics